<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038597</url>
  </required_header>
  <id_info>
    <org_study_id>DM01-072</org_study_id>
    <nct_id>NCT00038597</nct_id>
  </id_info>
  <brief_title>Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)</brief_title>
  <official_title>Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to see if giving the drug SCH66336 by mouth can improve the
      disease in patients with chronic or accelerated phase CML. The safety of this treatment will
      also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives for this study are two-fold:

        1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated
           phase CML in relation to response rate, duration of response, and survival.

        2. To assess the toxicity of SCH66366 in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">13</enrollment>
  <condition>Myelogenous Leukemia, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH66336</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Diagnosis of Philadelphia chromosome (Ph) -positive CML in chronic or accelerated
             phase;

          -  Failure to respond to or intolerance to imatinib mesylate (Gleevec);

          -  Age &gt;/= 16 years;

          -  Life expectancy of &gt;/= 2 months;

          -  Performance status 2 or better (Zubrod);

          -  Adequate renal and hepatic functions (creatinine and bilirubin &lt;/= 2 mg/dl);

          -  Adequate cardiac function;

          -  Not candidates for or have refused allogeneic transplantation;

          -  Patients should not be receiving azoles (ketoconazole, itraconazole, fluconazole),
             macrolides, HIV protease inhibitors, cyclosporin or anti-seizure drugs (phenobarbital,
             phenytoin, carbamazepine), rifampin or isoniazid.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDAnderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2002</study_first_submitted>
  <study_first_submitted_qc>June 3, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2002</study_first_posted>
  <last_update_submitted>January 20, 2012</last_update_submitted>
  <last_update_submitted_qc>January 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Philadelphia chromosome positive CML</keyword>
  <keyword>Myelogenous Leukemia, Chronic, Chronic Phase</keyword>
  <keyword>Myelogenous Leukemia, Chronic, Accelerated Phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

